Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	2,730	3,106	2,886	2,194	1,618
Short-Term Investments	8,115	4,636	2,809	1,393	1,597
Cash & Cash Equivalents	10,845	7,742	5,695	3,587	3,214
Cash Growth	40.07%	35.96%	58.76%	11.60%	14.39%
Receivables	5,667	5,329	6,037	4,115	2,786
Inventory	2,581	2,402	1,951	1,917	1,416
Other Current Assets	386.6	411.2	332.4	160.8	273.7
Total Current Assets	19,479	15,884	14,015	9,779	7,689
Property, Plant & Equipment	4,146	3,763	3,482	3,222	2,890
Long-Term Investments	5,397	6,592	6,838	3,136	3,257
Goodwill and Intangibles	1,039	915.5	6.7	0	0
Other Long-Term Assets	3,020	2,060	1,093	1,027	968.9
Total Long-Term Assets	13,601	13,330	11,420	7,384	7,116
Total Assets	33,080	29,215	25,435	17,163	14,805
Accounts Payable	606.6	589.2	564	475.5	418.1
Deferred Revenue	585.6	547.7	515.3	635.5	487.4
Current Debt	0	0	719.7	0	0
Other Current Liabilities	2,231	2,004	2,134	1,586	1,191
Total Current Liabilities	3,423	3,141	3,933	2,697	2,097
Long-Term Debt	2,703	2,701	1,980	2,696	713.9
Other Long-Term Liabilities	980.8	707.8	753.5	744.9	905
Total Long-Term Liabilities	3,684	3,409	2,734	3,441	1,619
Total Liabilities	7,107	6,551	6,666	6,138	3,716
Total Debt	2,703	2,701	2,700	2,696	713.9
Debt Growth	0.06%	0.06%	0.15%	277.60%	0.76%
Retained Earnings	27,260	23,307	18,968	10,893	7,380
Comprehensive Income	-80.9	-238.8	-26.2	29.3	21.1
Shareholders' Equity	25,973	22,664	18,769	11,025	11,090
Net Cash / Debt	8,142	5,041	2,995	891.3	2,500
Net Cash / Debt Growth	61.52%	68.31%	236.03%	-64.35%	18.99%
Net Cash Per Share	71.61	44.41	26.69	7.74	21.82
Working Capital	16,056	12,743	10,082	7,082	5,593
Book Value Per Share	243.42	211.62	177.57	102.47	101.55

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).